CC-Chemokine Receptor-2 Expression in Osteoblasts Contributes to Cartilage and Bone Damage during Post-Traumatic Osteoarthritis
Authors:
- Helen WillcocksonHWHelen Willcockson
- Huseyin OzkanHOHuseyin Ozkan
- José Valdés-FernándezJVJosé Valdés-Fernández
- Liubov ArbeevaLALiubov Arbeeva
- Esra MucahitEMEsra Mucahit
- Layla MusawwirLMLayla Musawwir
- Lola B. HooperLHLola B. Hooper
- Froilán Granero-MoltóFGFroilán Granero-Moltó
- Felipe PrósperFPFelipe Prósper
- Lara LongobardiLLLara Longobardi
Open Access
- 26 May 2023
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 13 (6) , 891
Abstract
In osteoarthritis (OA), bone changes are radiological hallmarks and are considered important for disease progression. The C-C chemokine receptor-2 (CCR2) has been shown to play an important role in bone physiology. In this study, we investigated whether Ccr2 osteoblast-specific inactivation at different times during post-traumatic OA (PTOA) progression improves joint structures, bone parameters, and pain. We used a tamoxifen-inducible Ccr2 inactivation in Collagen1α-expressing cells to obtain osteoblasts lacking Ccr2 (CCR2-Col1αKO). We stimulated PTOA changes in CCR2-Col1αKO and CCR2+/+ mice using the destabilization of the meniscus model (DMM), inducing recombination before or after DMM (early- vs. late-inactivation). Joint damage was evaluated at two, four, eight, and twelve weeks post-DMM using multiple scores: articular-cartilage structure (ACS), Safranin-O, histomorphometry, osteophyte size/maturity, subchondral bone thickness and synovial hyperplasia. Spontaneous and evoked pain were assessed for up to 20 weeks. We found that early osteoblast-Ccr2 inactivation delayed articular cartilage damage and matrix degeneration compared to CCR2+/+, as well as DMM-induced bone thickness. Osteophyte formation and maturation were only minimally affected. Late Collagen1α-Ccr2 deletion led to less evident improvements. Osteoblast-Ccr2 deletion also improved static measures of pain, while evoked pain did not change. Our study demonstrates that Ccr2 expression in osteoblasts contributes to PTOA disease progression and pain by affecting both cartilage and bone tissues.Keywords
Funding Information
- National Institutes of Health (R01AR070821, P30 AR072580, 872648)
- “Asociación de Amigos de la Universidad de Navarra” (R01AR070821, P30 AR072580, 872648)
This publication has 47 references indexed in Scilit:
- Subchondral bone in osteoarthritis: insight into risk factors and microstructural changesArthritis Research & Therapy, 2013
- CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritisProceedings of the National Academy of Sciences, 2012
- Brain activity for chronic knee osteoarthritis: Dissociating evoked pain from spontaneous painEuropean journal of pain, 2011
- Multiple roles for CCR2 during fracture healingDisease Models & Mechanisms, 2010
- Matrix metalloproteinase 13–deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte developmentArthritis & Rheumatism, 2009
- A complex pattern of chemokine receptor expression is seen in osteosarcomaBMC Cancer, 2008
- Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritisAnnals of the Rheumatic Diseases, 2007
- Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-β/bone morphogenic protein signallingArthritis Research & Therapy, 2007
- Symptoms and radiographic osteoarthritis: not as discordant as they are made out to be?Annals of the Rheumatic Diseases, 2007
- Transgenic Mice Expressing a Ligand-Inducible Cre Recombinase in Osteoblasts and OdontoblastsThe American Journal of Pathology, 2004